{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:25:36Z","timestamp":1785684336974,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00428-023-03648-w","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T03:22:20Z","timestamp":1695093740000},"page":"847-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Refining the application of PRAME\u2014a useful marker in high CSD and acral melanoma subtypes"],"prefix":"10.1007","volume":"483","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5268-721X","authenticated-orcid":false,"given":"Craig","family":"Wakefield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C. B. B.","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"6","key":"3648_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, Wang L, Edel MJ, Carl\u00e9e L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122(6):835\u2013847. https:\/\/doi.org\/10.1016\/j.cell.2005.07.003","journal-title":"Cell"},{"key":"3648_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1476-4598-9-226","volume":"9","author":"F Wadelin","year":"2010","unstructured":"Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM (2010) Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 9:226. https:\/\/doi.org\/10.1186\/1476-4598-9-226","journal-title":"Mol Cancer"},{"issue":"3","key":"3648_CR3","doi-asserted-by":"publisher","first-page":"e12770","DOI":"10.1111\/cpr.12770","volume":"53","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zou R, Wang J, Wang ZW, Zhu X (2020) The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer. Cell Prolif 53(3):e12770. https:\/\/doi.org\/10.1111\/cpr.12770","journal-title":"Cell Prolif"},{"issue":"2","key":"3648_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Leth\u00e9 B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199\u2013208. https:\/\/doi.org\/10.1016\/s1074-7613(00)80426-4","journal-title":"Immunity"},{"issue":"11","key":"3648_CR5","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","volume":"46","author":"M Kaczorowski","year":"2022","unstructured":"Kaczorowski M, Ch\u0142opek M, Kruczak A, Ry\u015b J, Lasota J, Miettinen M (2022) PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol 46(11):1467\u20131476. https:\/\/doi.org\/10.1097\/PAS.0000000000001944","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"3648_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ (2018) PRAME expression in melanocytic tumors. Am J Surg Pathol 42(11):1456\u20131465. https:\/\/doi.org\/10.1097\/PAS.0000000000001134","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"3648_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/cup.14130","volume":"49","author":"J McBride","year":"2022","unstructured":"McBride J, McAfee J, Piliang M, Bergfeld W, Fernandez A, Ronen S, Billings S, Ko J (2022) Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. J Cutan Pathol 49(3):220\u2013230. https:\/\/doi.org\/10.1111\/cup.14130","journal-title":"J Cutan Pathol"},{"issue":"7","key":"3648_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/cup.14226","volume":"49","author":"O Parra","year":"2022","unstructured":"Parra O, Linos K, Li Z, Yan S (2022) PRAME expression in melanocytic lesions of the nail. J Cutan Pathol 49(7):610\u2013617. https:\/\/doi.org\/10.1111\/cup.14226","journal-title":"J Cutan Pathol"},{"issue":"12","key":"3648_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","volume":"32","author":"A Toyama","year":"2019","unstructured":"Toyama A, Siegel L, Nelson AC et al (2019) Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas. Mod Pathol 32(12):1727\u20131733. https:\/\/doi.org\/10.1038\/s41379-019-0335-4","journal-title":"Mod Pathol"},{"issue":"8","key":"3648_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/cup.14232","volume":"49","author":"Z Evangelou","year":"2022","unstructured":"Evangelou Z, Linos K (2022) Nevus, melanoma, or something else? Mesenchymal neoplasms with melanocytic differentiation. J Cutan Pathol 49(8):747\u2013759. https:\/\/doi.org\/10.1111\/cup.14232","journal-title":"J Cutan Pathol"},{"issue":"7","key":"3648_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","volume":"44","author":"C Lezcano","year":"2020","unstructured":"Lezcano C, Jungbluth AA, Busam KJ (2020) Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol 44(7):893\u2013900. https:\/\/doi.org\/10.1097\/PAS.0000000000001492","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"3648_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/DAD.0000000000001951","volume":"43","author":"NT Harvey","year":"2021","unstructured":"Harvey NT, Peverall J, Acott N et al (2021) Correlation of FISH and PRAME immunohistochemistry in ambiguous superficial cutaneous melanocytic proliferations. Am J Dermatopathol 43(12):913\u2013920. https:\/\/doi.org\/10.1097\/DAD.0000000000001951","journal-title":"Am J Dermatopathol"},{"issue":"12","key":"3648_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/cup.13818","volume":"47","author":"SS Raghavan","year":"2020","unstructured":"Raghavan SS, Wang JY, Kwok S, Rieger KE, Novoa RA, Brown RA (2020) PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features. J Cutan Pathol 47(12):1123\u20131131. https:\/\/doi.org\/10.1111\/cup.13818","journal-title":"J Cutan Pathol"},{"key":"3648_CR14","unstructured":"WHO Classification of tumours editorial board. skin tumours. Lyon (France): International Agency for Research on Cancer; forthcoming. (WHO classification of tumours series, 5th ed.; vol. 12). https:\/\/publications.iarc.fr"},{"issue":"6","key":"3648_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/his.14615","volume":"80","author":"C Wakefield","year":"2022","unstructured":"Wakefield C, Heffron CCBB (2022) PRAME immunoexpression in benign fibroblasts - a diagnostic pitfall. Histopathology 80(6):1011\u20131013. https:\/\/doi.org\/10.1111\/his.14615","journal-title":"Histopathology"},{"key":"3648_CR16","doi-asserted-by":"publisher","first-page":"e8828579","DOI":"10.1155\/2020\/8828579","volume":"2020","author":"J Li","year":"2020","unstructured":"Li J, Yin J, Zhong J, Yang Z, Tang A, Li S (2020) Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta-analysis. BioMed Research International. 2020:e8828579. https:\/\/doi.org\/10.1155\/2020\/8828579","journal-title":"BioMed Research International."},{"issue":"3","key":"3648_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","volume":"99","author":"MT Epping","year":"2008","unstructured":"Epping MT, Hart AAM, Glas AM, Krijgsman O, Bernards R (2008) PRAME expression and clinical outcome of breast cancer. Br J Cancer 99(3):398\u2013403. https:\/\/doi.org\/10.1038\/sj.bjc.6604494","journal-title":"Br J Cancer"},{"issue":"1","key":"3648_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-018-1757-3","volume":"17","author":"G Al-Khadairi","year":"2019","unstructured":"Al-Khadairi G, Naik A, Thomas R, Al-Sulaiti B, Rizly S, Decock J (2019) PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med 17(1):9. https:\/\/doi.org\/10.1186\/s12967-018-1757-3","journal-title":"J Transl Med"},{"issue":"6","key":"3648_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","volume":"135","author":"G Gezgin","year":"2017","unstructured":"Gezgin G, Luk SJ, Cao J et al (2017) PRAME as a Potential Target for Immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol 135(6):541\u2013549. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0729","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"3648_CR20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S et al (2016) PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res 22(5):1234\u20131242. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2071","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3648_CR21","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.modpat.2022.100081","volume":"36","author":"LM Han","year":"2023","unstructured":"Han LM, Lee KW, Uludag G, Seider MI, Afshar AR, Bloomer MM, Pekmezci M (2023) Prognostic value of BAP1 and preferentially expressed antigen in melanoma (PRAME) Immunohistochemistry in uveal melanomas. Mod Pathol 36(4):100081. https:\/\/doi.org\/10.1016\/j.modpat.2022.100081","journal-title":"Mod Pathol"},{"issue":"7","key":"3648_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","volume":"11","author":"G Al-Khadairi","year":"2019","unstructured":"Al-Khadairi G, Decock J (2019) Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME? Cancers 11(7):984. https:\/\/doi.org\/10.3390\/cancers11070984","journal-title":"Cancers"},{"issue":"12","key":"3648_CR23","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.5858\/arpa.2020-0620-OA","volume":"145","author":"S Ronen","year":"2021","unstructured":"Ronen S, Al-Rohil RN, Keiser E et al (2021) Discordance in diagnosis of melanocytic lesions and its impact on clinical management: a melanoma referral center experience with 1521 cases. Arch Path Lab 145(12):1505\u20131515. https:\/\/doi.org\/10.5858\/arpa.2020-0620-OA","journal-title":"Arch Path Lab"},{"issue":"4","key":"3648_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/path.1061","volume":"196","author":"L Brochez","year":"2002","unstructured":"Brochez L, Verhaeghe E, Grosshans E et al (2002) Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 196(4):459\u2013466. https:\/\/doi.org\/10.1002\/path.1061","journal-title":"J Pathol"},{"issue":"42","key":"3648_CR25","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1038\/onc.2017.189","volume":"36","author":"WE Damsky","year":"2017","unstructured":"Damsky WE, Bosenberg M (2017) Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene 36(42):5771\u20135792. https:\/\/doi.org\/10.1038\/onc.2017.189","journal-title":"Oncogene"},{"issue":"11","key":"3648_CR26","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/jdv.18453","volume":"36","author":"C Dessinioti","year":"2022","unstructured":"Dessinioti C, Geller AC, Stratigos AJ (2022) A review of nevus-associated melanoma: what is the evidence? J Eur Acad Dermatol Venereol 36(11):1927\u20131936. https:\/\/doi.org\/10.1111\/jdv.18453","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3648_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1309\/AJCP4L5CJGKTJVDD","volume":"142","author":"D Shitara","year":"2014","unstructured":"Shitara D, Nascimento MM, Puig S et al (2014) Nevus-associated melanomas: clinicopathologic features. Am J Clin Pathol 142(4):485\u2013491. https:\/\/doi.org\/10.1309\/AJCP4L5CJGKTJVDD","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"3648_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/cancers15030856","volume":"15","author":"C Dessinioti","year":"2023","unstructured":"Dessinioti C, Befon A, Stratigos AJ et al (2023) The association of nevus-associated melanoma with common or dysplastic melanocytic nevus: a systematic review and meta-analysis. Cancers (Basel) 15(3):856. https:\/\/doi.org\/10.3390\/cancers15030856","journal-title":"Cancers (Basel)"},{"issue":"15","key":"3648_CR29","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.3390\/cancers13153864","volume":"13","author":"M Gassenmaier","year":"2021","unstructured":"Gassenmaier M, Hahn M, Metzler G et al (2021) Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers (Basel) 13(15):3864. https:\/\/doi.org\/10.3390\/cancers13153864","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3648_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/cup.14000","volume":"48","author":"AK Alomari","year":"2021","unstructured":"Alomari AK, Tharp AW, Umphress B, Kowal RP (2021) The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol 48(9):1115\u20131123. https:\/\/doi.org\/10.1111\/cup.14000","journal-title":"J Cutan Pathol"},{"issue":"9","key":"3648_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/cup.14267","volume":"49","author":"MK O\u2019Connor","year":"2022","unstructured":"O\u2019Connor MK, Dai H, Fraga GR (2022) PRAME immunohistochemistry for melanoma diagnosis: a STARD-compliant diagnostic accuracy study. J Cutan Pathol 49(9):780\u2013786. https:\/\/doi.org\/10.1111\/cup.14267","journal-title":"J Cutan Pathol"},{"issue":"7","key":"3648_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/cup.13958","volume":"48","author":"ME Lohman","year":"2021","unstructured":"Lohman ME, Steen AJ, Grekin RC, North JP (2021) The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol 48(7):856\u2013862. https:\/\/doi.org\/10.1111\/cup.13958","journal-title":"J Cutan Pathol"},{"issue":"7","key":"3648_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/his.14312","volume":"78","author":"SE Gradecki","year":"2021","unstructured":"Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA (2021) PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 78(7):1000\u20131008. https:\/\/doi.org\/10.1111\/his.14312","journal-title":"Histopathology"},{"issue":"8","key":"3648_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/DAD.0000000000001607","volume":"42","author":"D Tio","year":"2020","unstructured":"Tio D, Willemsen M, Krebbers G et al (2020) Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma. Am J Dermatopathol 42(8):625. https:\/\/doi.org\/10.1097\/DAD.0000000000001607","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"3648_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/his.14814","volume":"82","author":"Y-P Chen","year":"2023","unstructured":"Chen Y-P, Zhang W-W, Qiu Y-T, Ke L-F, Chen H, Chen G (2023) PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. Histopathology. 82(2):285\u2013295. https:\/\/doi.org\/10.1111\/his.14814","journal-title":"Histopathology."},{"issue":"9","key":"3648_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/cup.14286","volume":"49","author":"JM Plotzke","year":"2022","unstructured":"Plotzke JM, Zoumberos NA, Hrycaj SM, Harms PW, Bresler SC, Chan MP (2022) PRAME expression is similar in scar and desmoplastic melanoma. J Cutan Pathol 49(9):829\u2013832. https:\/\/doi.org\/10.1111\/cup.14286","journal-title":"J Cutan Pathol"},{"issue":"7","key":"3648_CR37","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.pathol.2022.05.012","volume":"54","author":"RV Rawson","year":"2022","unstructured":"Rawson RV, Shteinman ER, Ansar S et al (2022) Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. J Pathol 54(7):863\u2013873. https:\/\/doi.org\/10.1016\/j.pathol.2022.05.012","journal-title":"J Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03648-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03648-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03648-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:04:14Z","timestamp":1701860654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03648-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03648-w","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Clinical Research Ethics Committee of the participating institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}